Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP75YK)

• Drug Name: L-741742 Drug Info
• Synonyms: L-741742; UNII-C5B89UM05U; CHEMBL444309; C5B89UM05U; L 741742; L-741,742; L741742; Cmpepi-3; Tocris-1004; Biomol-NT_000048; GTPL3302; SCHEMBL1388774; BPBio1_001096; DTXSID0043894; CHEBI:92229; ZINC602172; AC1L3203; BDBM50050476; NCGC00024933-02; NCGC00024933-01; L016523; L 741,742; BRD-K13211965-001-02-2; BRD-K13211965-003-01-0; BRD-K13211965-001-01-4; 5-(4-chlorophenyl)-4-methyl-3-(1-phenethylpiperidin-4-yl)-1,2-oxazole; 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 133008
  ChEBI ID: CHEBI:92229
  CAS Number: CAS 156337-32-5
  TTD Drug ID: DMP75YK

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D3 receptor (D3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cariprazine	DMJYDVK	Bipolar disorder	6A60	Approved	[4]
Pramipexole	DMNMW9R	Parkinson disease	8A00.0	Approved	[5]
Ropinirole	DMA6S1D	Parkinson disease	8A00.0	Approved	[5]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[6]
P2B-001	DM9PVHX	Parkinson disease	8A00.0	Phase 3	[7]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[8]
ONC201	DMM5SCF	Endometrial cancer	2C76	Phase 2	[9]
TAK-906	DMBQD9H	Diabetic gastroparesis	DA41.00	Phase 2	[10]
GSK598809	DMGU05N	Drug abuse	6C4G.1Z	Phase 2	[11]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[11]

Drug(s) Targeting Dopamine D4 receptor (D4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[5]
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[12]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[6]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[8]
L-745,870	DMTGR25	Psychotic disorder	6A20-6A25	Phase 2	[13]
NGD 94-1	DMM1Y8F	Schizophrenia	6A20	Phase 1	[14]
ABT-724	DMDQVY4	Erectile dysfunction	HA01.1	Discontinued in Phase 2	[15]
Lu-35138	DMQ7A35	Psychotic disorder	6A20-6A25	Discontinued in Phase 2	[16]
NGD-94-4	DMZ9WLO	Schizophrenia	6A20	Discontinued in Phase 1	[17]
PD-165167	DMD0GB4	Schizophrenia	6A20	Preclinical	[14]

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[18]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[19]
Zonisamide	DM0DTF7	Alcohol dependence	6C40.2	Approved	[20]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[21]
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[22]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[23]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[24]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[25]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[26]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[27]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.3 (SCN3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[22]
Aryl carboxamide derivative 1	DMTZRCW	N. A.	N. A.	Patented	[28]
Aryl carboxamide derivative 2	DM146TA	N. A.	N. A.	Patented	[28]
Pyrimidine derivative 1	DMN9VQM	N. A.	N. A.	Patented	[28]
Pyrrolo-pyridinone derivative 6	DMXGNP8	N. A.	N. A.	Patented	[28]
Pyrrolo-pyridinone derivative 5	DMK2FSY	N. A.	N. A.	Patented	[28]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[29]
U-92032	DMTYO3P	N. A.	N. A.	Terminated	[30]
PD-85639	DMNUKB4	N. A.	N. A.	Terminated	[22]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[31]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Inhibitor	[2]
Dopamine D4 receptor (D4R)	TTE0A2F	DRD4_HUMAN	Inhibitor	[2]
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Inhibitor	[3]
Voltage-gated sodium channel alpha Nav1.3 (SCN3A)	TTAXZ0K	SCN3A_HUMAN	Inhibitor	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3302).
• [2] 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. J Med Chem. 1996 May 10;39(10):1943-5.
• [3] 1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) rece... J Med Chem. 1999 Jul 15;42(14):2706-15.
• [4] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [7] Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [12] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [13] Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
• [14] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [15] Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
• [17] I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.
• [18] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [19] Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
• [20] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [21] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [22] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [23] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [24] Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
• [25] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [26] In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
• [27] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [28] Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
• [29] Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke. J Med Chem. 2002 Aug 15;45(17):3755-64.
• [30] Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
• [31] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580).